Ludwig Boltzmann Institute   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Vienna Austria (1992)

Organization Overview

First Clinical Trial
2005
NCT00531024
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Ludwig Boltzmann Foundation for Cardiovascular Research | Ludwig Boltzmann Gesellschaft | Ludwig Boltzmann Institute for Biomicroscopic Lasersurgery | Ludwig Boltzmann Institute for Digital Health and Prevention | Ludwig Boltzmann Institute for Lung Vascular Research | Ludwig Boltzmann Institute for retinology and biomicroscopic Lasersurgery | Ludwig Boltzmann Institute of Aging Research | Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation | Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation | Ludwig-Boltzmann-Institut fuer Rheumatologie und Balneologie | LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Atherosclerosis (Phase 2)

Back Pain (Phase 2)

Cardiac Output, Low (Phase 2)

Edema (Phase 3)

Familial Primary Pulmonary Hypertension (Phase 2)

Hypertension (Phase 4)

Low Back Pain (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Macular Degeneration (Phase 3)

Macular Edema (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 15